


What is claimed:

1. A compound of formula 1:



wherein

R_1 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;

R_2 is hydroxy, amino, or lower alkoxy;

R_3 is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;

R_4 is H or lower alkyl;

and pharmaceutically acceptable salts and esters thereof.

2. The compound of claim 1, wherein R_4 is methyl.

3. The compound of claim 2, wherein R_2 is amino.

4. The compound of claim 3, wherein R_1 is pyridylmethyl.

5. The compound of claim 4, wherein R_3 is propanoyl.

6. The compound of claim 4, wherein R_3 is 3-methylbutanoyl.

7. The compound of claim 4, wherein R_3 is butanoyl.

8. The compound of claim 4, wherein R_3 is H.

9. The compound of claim 3, wherein R₁ is 4-(trifluoromethyl)benzyl.

10. The compound of claim 9, wherein R₃ is methoxyacetyl.

11. The compound of claim 9, wherein R₃ is H.

12. The compound of claim 9, wherein R₃ is aminoacetyl.

13. The compound of claim 9, wherein R₃ is propanoyl.

14. The compound of claim 9, wherein R₃ is 3-methylbutanoyl.

15. The compound of claim 3, wherein R₁ is 4-fluorobenzyl.

16. The compound of claim 15, wherein R₃ is methoxyacetyl.

17. The compound of claim 15, wherein R₃ is H.

18. The compound of claim 3, wherein R₁ is 4-methoxybenzyl and R₃ is H.

19. The compound of claim 3, wherein R₁ is cyclohexyl, and R₃ is H.

20. The compound of claim 3, wherein R₁ is 3-methylbutyl.

21. The compound of claim 20, wherein R₃ is methoxyacetyl.


22. The compound of claim 20, wherein R₃ is 3-aminopropanoyl.

23. The compound of claim 3, wherein R₁ is 4-chlorobenzyl, and R₃ is butanoyl.

009077-84520260

Sub
B5

24. A pharmaceutical composition, comprising:
a compound of formula 1:



wherein

R₁ is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl,
substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy,
lower alkoxy, amino, lower alkyl-amino, and nitro;

R₂ is hydroxy, amino, or lower alkoxy;

R₃ is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;

R₄ is H or lower alkyl;

or a pharmaceutically acceptable salts and esters thereof; and

a pharmaceutically acceptable excipient.


Sub
M6

09707548-110600

25. A method of inhibiting GSK3, comprising:

providing active GSK3; and

contacting said GSK3 with a compound of formula 1:



wherein

R_1 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;

R_2 is hydroxy, amino, or lower alkoxy;

R_3 is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;


R_4 is H or lower alkyl;

and pharmaceutically acceptable salts and esters thereof.

009071-848-110600

26. A method for treating a disorder mediated by GSK3,
comprising:

providing an effective amount of a compound of formula 1:



wherein

R₁ is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl,
substituted with 0-3 substituents selected from lower alkyl, halo,
hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;

R₂ is hydroxy, amino, or lower alkoxy;

R₃ is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-
acyl;

R₄ is H or lower alkyl;

or a pharmaceutically acceptable salt or ester thereof; and
administering said composition to a subject having a disorder mediated by
GSK3.

27. The method of claim 26, wherein said disorder is selected from
the group consisting of diabetes and Alzheimer's disease.

009071-84520260